Orca Bio’s T cell therapy may help blood cancer patients avoid transplant issuesnews2025-03-17T15:16:35+00:00March 17th, 2025|Endpoints News|
GRO Biosciences, working on recoded organisms, cuts most staffnews2025-03-17T12:45:21+00:00March 17th, 2025|Endpoints News|
AstraZeneca reveals first-in-human data for B7-H4-targeting ADC in endometrial cancernews2025-03-17T11:20:23+00:00March 17th, 2025|Endpoints News|
Avidity heads to FDA with exon 44 skipping Duchenne muscular dystrophy drugnews2025-03-17T11:00:15+00:00March 17th, 2025|Endpoints News|
Boston Pharma mulls IPO amid MASH momentumnews2025-03-14T19:00:00+00:00March 14th, 2025|Endpoints News|
Pfizer terminates an early-stage STING agonist trialnews2025-03-14T07:54:55+00:00March 14th, 2025|Endpoints News|
Amgen reports more Phase 3 Uplizna data in myasthenia gravis ahead of FDA filingnews2025-03-13T11:22:19+00:00March 13th, 2025|Endpoints News|
#CROI25: Merck’s troubled HIV drug heads to regulators; ViiV seeks longer-acting HIV treatmentnews2025-03-12T15:25:09+00:00March 12th, 2025|Endpoints News|
Ono licenses rare blood disease drug from Ionis for $280M upfrontnews2025-03-12T10:34:49+00:00March 12th, 2025|Endpoints News|
Updated: Zealand partners with Roche on its amylin analog in a deal worth up to $5.3Bnews2025-03-12T08:10:30+00:00March 12th, 2025|Endpoints News|
